Patient with Recurrent Hypoglycemia Caused by Malignant Giant Insulinoma

Authors

DOI:

https://doi.org/10.24293/ijcpml.v29i2.1832

Keywords:

Endocrine tumor, hypoglycemia, malignant giant insulinoma

Abstract

Insulinoma is a functional endocrine tumor in the pancreas and the most common cause of hypoglycemia due to endogenic hyperinsulinism. Insulinoma is a rare case, with an incidence of 1-4 cases per million people each year. Malignant insulinoma is an insulinoma that is proven to metastasize to other tissues and only happens in 5-10% of insulinoma cases. Insulinoma with a size >9 cm is classified as giant insulinoma. Since 1927, fewer than 40 cases of giant insulinoma have been reported. 56 years old female was referred from a private hospital with the chief complaint of decreased consciousness due to recurrent hypoglycemia. On physical examination, palpable ±12x4 cm solid mass with an uneven surface in the epigastric region. Laboratory tests found an increase in c-peptide, fasting insulin, and liver function tests. A contrast CT scan found a heterogeneous solid mass 7.6x8.6x13.6 cm in cauda of the pancreas and hepatomegaly with multiple metastatic nodules. Results of pancreas and liver biopsy showed poorly differentiated carcinoma that metastasizes to the liver. In this case, based on patient history, physical and other examinations, it can be concluded that the patient was diagnosed with an observation of recurrent hypoglycemia caused by giant insulinoma with liver metastases.

Downloads

Download data is not yet available.

Author Biographies

Clareza Arief Wardhana, Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

Anak Agung Wiradewi Lestari, Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

I Nyoman Wande, Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

Department of Clinical Pathology Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

References

Miranda G. Malignant insulinoma chemotherapy resistant, pancreatic neuroendocrine tumour of uncertain prognosis. Journal of Clinical and Translational Endocrinology, 2018; 8: 16–8.

Backi SA, Saber T, Rassi ZE. A rare entity of malignant insulinoma diagnosed after 30 years of clinical manifestation of hypoglycemia: A case report and literature review. J Clin Images Med Case Rep, 2021; 2(6): 1432.

Vasikasin V, Watthanatham J, Napatharatip P, Thermmaturapoj S. Giant insulinoma in 15 year-old-man: A case report. International Journal of Surgery Case Reports, 2016; 24: 135-8.

Ueda K, Taira T, Hakoda H, Nakata S, Okata S, Nagai T, et al. Giant insulinoma: Report of a case and review of published reports. Surgical Case Reports, 2016; 2: 136-43.

Cigrovski Berkovic M, Ulamec M, Marinovic S, Balen I, Mrzljak A. Malignant insulinoma: Can we predict the long-term outcomes?. World J Clin Cases, 2022; 10(16): 5124-32.

Wang T, Vu A, Mereu L, Ghosh M. Malignant insulinoma in a patient with hypoglycemia. CMAJ, 2022; 194 (9); 332-5.

Taye A. Libutti SK. Diagnosis and management of insulinoma: current best practice and ongoing developments. Research and Reports in Endocrine Disorders, 2015; 5: 125-33.

Cavalcanti MS, Gonen M, Klimstra DS. The ENETS/WHO grading system for neuroendicrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitaions and proposals for modification. Int J Endocr Oncol, 2018; 3(3):203-19.

Inzani F, Petrone G, Rindi G. The New World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin N Am, 2018; 47: 463-70.

Bozkirli E, Bakiner O, Abali H, Andic C, Fuat A, Kayasellcuk F, et al. A Case of inoperable malignant insulinoma with resistant hypoglycemia who experienced the most significant clinical improvement with everolimus. Hindawi, 2016; 10: 1-6.

Downloads

Submitted

2021-01-20

Accepted

2023-01-04

Published

2023-05-05

How to Cite

[1]
Wardhana, C.A., Lestari, A.A.W. and Wande, I.N. 2023. Patient with Recurrent Hypoglycemia Caused by Malignant Giant Insulinoma . INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 29, 2 (May 2023), 200–205. DOI:https://doi.org/10.24293/ijcpml.v29i2.1832.

Issue

Section

Case Report